Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 294

1.

What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?

Gibson RJ, Bowen JM, Coller JK.

Future Oncol. 2015 Aug 13:1-3. [Epub ahead of print] No abstract available.

2.

ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis.

Van Sebille YZ, Gibson RJ, Wardill HR, Bowen JM.

Cancer Treat Rev. 2015 Jul;41(7):646-52. doi: 10.1016/j.ctrv.2015.05.011. Epub 2015 Jun 6. Review.

PMID:
26073491
3.

Extramedullary hematopoiesis in a sentinel lymph node as an early sign of chronic myelomonocytic leukemia.

Bowen JM, Perry AM, Quist E, Akhtari M.

Case Rep Pathol. 2015;2015:594970. doi: 10.1155/2015/594970. Epub 2015 Apr 16.

4.

Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma.

Chiam K, Wang T, Watson DI, Mayne GC, Irvine TS, Bright T, Smith L, White IA, Bowen JM, Keefe D, Thompson SK, Jones ME, Hussey DJ.

J Gastrointest Surg. 2015 Jul;19(7):1208-15. doi: 10.1007/s11605-015-2829-9. Epub 2015 May 6.

PMID:
25943911
5.

Editorial Comment: Does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner?

Wardill HR, Van Sebille YZ, Bowen JM, Gibson RJ.

Curr Opin Support Palliat Care. 2015 Jun;9(2):155-6. doi: 10.1097/SPC.0000000000000139. No abstract available.

PMID:
25872125
6.

Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.

Bowen JM, White I, Smith L, Tsykin A, Kristaly K, Thompson SK, Karapetis CS, Tan H, Game PA, Irvine T, Hussey DJ, Watson DI, Keefe DM.

Support Care Cancer. 2015 Mar 27. [Epub ahead of print]

PMID:
25814442
7.

Evidence-based decision-making 3: Health technology assessment.

O'Reilly D, Campbell K, Vanstone M, Bowen JM, Schwartz L, Assasi N, Goeree R.

Methods Mol Biol. 2015;1281:417-41. doi: 10.1007/978-1-4939-2428-8_25.

PMID:
25694325
8.

Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity.

Wardill HR, Van Sebille YZ, Mander KA, Gibson RJ, Logan RM, Bowen JM, Sonis ST.

Cancer Treat Rev. 2015 Feb;41(2):122-8. doi: 10.1016/j.ctrv.2014.11.005. Epub 2014 Dec 5. Review.

PMID:
25512119
9.

Of Marfan's syndrome, mice, and medications.

Bowen JM, Connolly HM.

N Engl J Med. 2014 Nov 27;371(22):2127-8. doi: 10.1056/NEJMe1412950. Epub 2014 Nov 18. No abstract available.

PMID:
25405389
10.

Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study.

Coller JK, White IA, Logan RM, Tuke J, Richards AM, Mead KR, Karapetis CS, Bowen JM.

Support Care Cancer. 2015 May;23(5):1233-6. doi: 10.1007/s00520-014-2481-z. Epub 2014 Oct 16.

PMID:
25318697
11.

Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis.

Al-Azri AR, Gibson RJ, Bowen JM, Stringer AM, Keefe DM, Logan RM.

J Oral Pathol Med. 2015 Jul;44(6):459-67. doi: 10.1111/jop.12255. Epub 2014 Sep 12.

PMID:
25213123
12.

Development of the rat model of lapatinib-induced diarrhoea.

Bowen JM.

Scientifica (Cairo). 2014;2014:194185. doi: 10.1155/2014/194185. Epub 2014 Jul 7. Review.

13.

Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.

Bowen JM, Mayo BJ, Plews E, Bateman E, Wignall A, Stringer AM, Boyle FM, Keefe DM.

Cancer Chemother Pharmacol. 2014 Sep;74(3):617-27. doi: 10.1007/s00280-014-2519-4. Epub 2014 Jul 24.

PMID:
25055934
14.

Evaluation of a chronic disease management system for the treatment and management of diabetes in primary health care practices in Ontario: an observational study.

O'Reilly DJ, Bowen JM, Sebaldt RJ, Petrie A, Hopkins RB, Assasi N, MacDougald C, Nunes E, Goeree R.

Ont Health Technol Assess Ser. 2014 Apr 1;14(3):1-37. eCollection 2014.

15.

Lymphoma diagnosis at an academic centre: rate of revision and impact on patient care.

Bowen JM, Perry AM, Laurini JA, Smith LM, Klinetobe K, Bast M, Vose JM, Aoun P, Fu K, Greiner TC, Chan WC, Armitage JO, Weisenburger DD.

Br J Haematol. 2014 Jul;166(2):202-8. doi: 10.1111/bjh.12880. Epub 2014 Apr 4.

PMID:
24697285
16.

New pharmacotherapy options for chemotherapy-induced alimentary mucositis.

Wardill HR, Bowen JM, Gibson RJ.

Expert Opin Biol Ther. 2014 Mar;14(3):347-54. doi: 10.1517/14712598.2014.874412. Epub 2014 Jan 6. Review.

PMID:
24387716
17.

Systematic review and meta-analysis of the benefits of out-of-hospital 12-lead ECG and advance notification in ST-segment elevation myocardial infarction patients.

Nam J, Caners K, Bowen JM, Welsford M, O'Reilly D.

Ann Emerg Med. 2014 Aug;64(2):176-86, 186.e1-9. doi: 10.1016/j.annemergmed.2013.11.016. Epub 2013 Dec 22. Review.

PMID:
24368054
18.

A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada.

Whelan JP, Bowen JM, Burke N, Woods EA, McIssac GP, Hopkins RB, O'Reilly DJ, Xie F, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride JE.

Can Urol Assoc J. 2013 Sep-Oct;7(9-10):335-41. doi: 10.5489/cuaj.180.

19.

Irinotecan disrupts tight junction proteins within the gut : implications for chemotherapy-induced gut toxicity.

Wardill HR, Bowen JM, Al-Dasooqi N, Sultani M, Bateman E, Stansborough R, Shirren J, Gibson RJ.

Cancer Biol Ther. 2014 Feb;15(2):236-44. doi: 10.4161/cbt.27222. Epub 2013 Dec 6.

20.

TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?

Wardill HR, Gibson RJ, Logan RM, Bowen JM.

Int J Cancer. 2014 Dec 1;135(11):2483-92. doi: 10.1002/ijc.28656. Epub 2014 Jan 10. Review.

PMID:
24310924
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk